MHSRS, 2019 – Renick, et al. “The topical metalloprotease SN514 enhances antimicrobial activity against bacterial biofilms”
MHSRS, 2022 – Natesan, et al. “Enzymatic debridement of burn wounds using the proteolytic gel SN514”
MHSRS, 2019 – Renick, et al. “The topical metalloprotease SN514 enhances antimicrobial activity against bacterial biofilms”
Presentation at the European Wound Management Association, Barcelona ES 2025 Wound Management Association, Barcelona ES 2025
Presentation at the Innovations in Wound Healing, Islamorada Florida US Dec 4, 2024
Slade, H.B., Reece, B.T., McCoy, N.D., et al. (2025) “Effects of a New Enzymatic Debrider (SN514-066b) on Eschar Protein Digestion, Burn Wound Debridement, and Healthy Skin Irritation.” Adv Wound Care 14
Effects of a New Enzymatic Debrider (SN514-066b) on Eschar Protein Digestion, Burn Wound Debridement, and Healthy Skin Irritation | Advances in Wound Care
Atiyeh, B., Makkawi, K., Beaineh, P. (2024). “Burn Wounds and Enzymatic Debridement (ED)-Past, Present, and Future.” J Burn Care Res 45(4): 864-876 DOI: 10.1093/jbcr/irae059.
Stone, R., Jockheck-Clark, A. R., Natesan, S., et al. (2020). “Enzymatic Debridement of Porcine Burn Wounds via a Novel Protease, SN514.” J Burn Care Res 41(5): 1015-1028 DOI: 10.1093/jbcr/iraa111.
Effects of SN514-066b on Eschar Protein Digestion, Burn Wound Debridement and Healthy Skin Irritation – The Poster presented at the Innovations in Wound Healing – Annual Conference held December 3-6, 2024 in Islamorada, FL (https://whinnovations.com/).
SERDA Therapeutics Announces Completion of First Phase 1 Clinical Study of SN514.
AMSTERDAM, THE NETHERLANDS, 29 July 2024. SERDA Therapeutics, a biopharmaceutical company focused on developing improved treatments for burns and chronic wounds, today announced completion of its first Phase 1 human clinical study of SN514 hydrogel, an innovative enzymatic wound debriding agent, in healthy adult volunteers. In preclinical studies, SN514 hydrogel showed outstanding efficacy and speed […]